ETF甄选 | 两部门印发《支持创新药高质量发展的若干措施》，创新药、黄金股、银行等相关ETF表现亮眼！

Market Overview - The market experienced fluctuations with mixed performance among the three major indices, where the Shanghai Composite Index rose by 0.39%, the Shenzhen Component Index increased by 0.11%, while the ChiNext Index fell by 0.24% [1] Sector Performance - Sectors such as glass fiber, chemical pharmaceuticals, and biological products showed significant gains, while multi-financial, software development, and battery sectors faced declines [1] - Major capital inflows were observed in the chemical pharmaceuticals, electric power, and banking sectors [1] Innovation Drug Sector - The National Healthcare Security Administration and the National Health Commission issued measures to support the high-quality development of innovative drugs, emphasizing the use of medical insurance data for drug research and development [2] - According to Guojin Securities, the innovative drug sector is currently undervalued, with an increase in the number and quality of new drug approvals in China since the beginning of 2025 [2] Gold Market Outlook - U.S. President Trump criticized the Federal Reserve for not lowering interest rates, with expectations of a rate cut later this year and three cuts next year [3] - China Galaxy Securities predicts that COMEX gold prices may steadily break through $3,300 per ounce, with potential to reach $3,500 in extreme risk scenarios [3] Banking Sector Analysis - The People's Bank of China indicated a continuation of accommodative monetary policy, with expectations for further interest rate cuts and a potential reserve requirement ratio reduction [3] - Guosheng Securities highlighted the ongoing attractiveness of the banking sector, citing a dividend yield of 5.13% compared to a 10-year government bond yield of 1.66%, indicating a significant yield spread [4]